Thomas Göhler

516 total citations
34 papers, 225 citations indexed

About

Thomas Göhler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas Göhler has authored 34 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Thomas Göhler's work include Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (12 papers) and Breast Cancer Treatment Studies (10 papers). Thomas Göhler is often cited by papers focused on Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (12 papers) and Breast Cancer Treatment Studies (10 papers). Thomas Göhler collaborates with scholars based in Germany, Austria and Estonia. Thomas Göhler's co-authors include Peter Malfertheiner, Matthias Walther, Rudolf Stauber, Ronald Koschny, Guido Gerken, Peter R. Galle, Tom M. Ganten, Axel Hinke, Thomas Decker and Hans Tesch and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Thomas Göhler

31 papers receiving 220 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Göhler Germany	10	132	67	56	46	39	34	225
F. Losa Gaspà Spain	4	136 1.0×	62 0.9×	35 0.6×	17 0.4×	22 0.6×	9	188
Xuxian Chen China	6	208 1.6×	62 0.9×	135 2.4×	26 0.6×	22 0.6×	14	266
Rossana Intini Italy	9	233 1.8×	82 1.2×	63 1.1×	22 0.5×	59 1.5×	29	307
Michel Gatineau France	8	174 1.3×	60 0.9×	21 0.4×	33 0.7×	102 2.6×	21	275
Nisha L. Jacobs United States	6	201 1.5×	77 1.1×	37 0.7×	57 1.2×	24 0.6×	10	279
Sanjeev Deva New Zealand	9	179 1.4×	60 0.9×	29 0.5×	15 0.3×	64 1.6×	37	249
Loretta D’Onofrio Italy	8	137 1.0×	80 1.2×	77 1.4×	93 2.0×	60 1.5×	18	299
Duc Le Canada	10	153 1.2×	97 1.4×	37 0.7×	21 0.5×	67 1.7×	26	308
Javier Sastre Valera Spain	6	288 2.2×	126 1.9×	35 0.6×	100 2.2×	34 0.9×	15	348
Yiming Zhao China	10	131 1.0×	72 1.1×	64 1.1×	16 0.3×	122 3.1×	19	293

Countries citing papers authored by Thomas Göhler

Since Specialization

Citations

This map shows the geographic impact of Thomas Göhler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Göhler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Göhler more than expected).

Fields of papers citing papers by Thomas Göhler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Göhler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Göhler. The network helps show where Thomas Göhler may publish in the future.

Co-authorship network of co-authors of Thomas Göhler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Göhler. A scholar is included among the top collaborators of Thomas Göhler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Göhler. Thomas Göhler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harbeck, Nadia, Ronald Kates, Timo Schinköthe, et al.. (2023). Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. Cancer Treatment Reviews. 121. 102631–102631. 6 indexed citations

Brucker, Cosima, Thomas Decker, PA Fasching, et al.. (2023). 441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study. Annals of Oncology. 34. S366–S367. 1 indexed citations

Decker, Thomas, Cosima Brucker, Peter A. Fasching, et al.. (2023). 409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)). Annals of Oncology. 34. S354–S355. 2 indexed citations

Fasching, Peter A., Cosima Brucker, Thomas Decker, et al.. (2023). Abstract P4-01-03: Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA. Cancer Research. 83(5_Supplement). P4–1. 2 indexed citations

Harbeck, Nadia, Ronald Kates, Timo Schinköthe, et al.. (2023). 195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. ESMO Open. 8(1). 101384–101384. 1 indexed citations

Hecht, Markus, D Hahn, Matthias Hautmann, et al.. (2021). A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer. Cancers. 13(14). 3413–3413. 5 indexed citations

Stintzing, Sebastian, G Hübner, Jörg Schröder, et al.. (2021). P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC. Annals of Oncology. 32. S116–S116.

Hecht, Markus, D Hahn, Matthias Hautmann, et al.. (2020). Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer. 20(1). 933–933. 9 indexed citations

Uhlig, Johannes, P. Stübs, Lutz Müller, et al.. (2020). 457P 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE. Annals of Oncology. 31. S436–S436. 1 indexed citations

10.

Dall, Peter, Thorsten Koch, Thomas Göhler, et al.. (2018). Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study. BMC Cancer. 18(1). 51–51. 10 indexed citations

11.

Dall, Peter, Thorsten Koch, Thomas Göhler, et al.. (2017). Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. The Oncologist. 22(2). 131–138. 9 indexed citations

12.

Decker, Thomas, Friedrich Overkamp, Siegfried Rösel, et al.. (2017). A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). BMC Cancer. 17(1). 499–499. 22 indexed citations

13.

Schmoll, Hans‐Joachim, Benjamin Garlipp, Christian Junghanß, et al.. (2017). FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis. Annals of Oncology. 28. iii152–iii152. 1 indexed citations

14.

Stein, Alexander, Julia Quidde, Thomas Göhler, et al.. (2016). Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study. BMC Cancer. 16(1). 82–82. 11 indexed citations

15.

Hecht, Markus, D Hahn, Dirk Beutner, et al.. (2016). Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial). Annals of Oncology. 27. vi343–vi343. 4 indexed citations

16.

Schmoll, Hans‐Joachim, Benjamin Garlipp, Christian Junghanß, et al.. (2016). FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA). Annals of Oncology. 27. vi560–vi560. 1 indexed citations

17.

Dall, Peter, Thomas Göhler, Christian Lerchenmüller, et al.. (2015). Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. Journal of Geriatric Oncology. 6(6). 462–469. 19 indexed citations

18.

Jackisch, Christian, Manfred Welslau, Winfried Schoenegg, et al.. (2014). Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany. The Breast. 23(5). 603–608. 15 indexed citations

19.

Bergmann, Lothar, Thomas Steiner, Peter J. Goebell, et al.. (2014). Evaluation of Safety, Tolerability and Activity of Temsirolimus in Patients (Pts) with Advanced or Metastatic Renal Cell Carcinoma (A/Mrcc) in Routine Clinical Practice. Annals of Oncology. 25. iv296–iv296. 2 indexed citations

20.

Siedentopf, Friederike, et al.. (2009). Capecitabine in the Routine Treatment of Advanced Breast Cancer: Results from a Non-Interventional Observational Study in 870 Patients. Onkologie. 32(11). 631–636. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact